Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,799 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Allergies Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of Sitting and Moderate Exercise on Plasma Insulin and Glucose Responses to an Oral Glucose Tolerance Test

NCT04195165
View directory record Official record
Conditions
Sedentary Behavior, Insulin Sensitivity, Sedentary Lifestyle
Interventions
SIT, ACTIVE, EX
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 17, 2026, 4:31 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects

NCT01842607
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
Long Beach, California • Newport Beach, California • Riverside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 17, 2026, 4:31 AM EDT
Completed Not applicable Interventional Results available

Computer-Delivered Intervention for Individuals With Obesity and Elevated Anxiety Sensitivity

NCT03917901
View directory record Official record
Conditions
Obesity, Anxiety Sensitivity, Eating, Physical Activity
Interventions
Anxiety Sensitivity Training, Health Control
Other
Lead sponsor
University of Houston
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 17, 2026, 4:31 AM EDT
Recruiting Phase 2 Interventional

A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

NCT07532265
View directory record Official record
Conditions
Severe Asthma
Interventions
Frevecitinib, Placebo
Drug
Lead sponsor
Kinaset Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Lancaster, California • San Jose, California • Brandon, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 17, 2026, 4:31 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

In-Vivo Bleeding Volume Test for Platelet-Aspirin Interaction

NCT01047722
View directory record Official record
Conditions
Healthy
Interventions
Aspirin ingestion followed by doing a Bleeding Volume Test, Gatorade Placebo followed by Bleeding Volume Test.
Drug · Procedure
Lead sponsor
Klein, Jeffrey A., M.D.
Individual
Eligibility
18 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
Newport Beach, California • San Juan Capistrano, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Oct 17, 2026, 4:31 AM EDT
Completed Phase 3 Interventional Results available

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

NCT02799602
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
58
States / cities
Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 17, 2026, 4:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MRI for Non-Invasive Imaging in Neonates and Children

NCT02163681
View directory record Official record
Conditions
Healthy, Cystic Fibrosis (CF), Asthma, Bronchopulmonary Dysplasia (BPD)
Interventions
Hyperpolarized Helium-3 MRI of the chest
Drug
Lead sponsor
University of Virginia
Other
Eligibility
4 Months to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 17, 2026, 4:31 AM EDT
Completed Phase 2 Interventional

A Study of BRT-FC-83C for the Treatment of Atopic Dermatitis

NCT00883311
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
BRT-FC-83C
Device
Lead sponsor
Biomed Research & Technologies, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 17, 2026, 4:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Mechanisms of Asthma

NCT00595153
View directory record Official record
Conditions
Asthma
Interventions
Pulmicort
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2014 · Synced Oct 17, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis

NCT05757856
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
NDX-3315, NDX-3324, SPECT/CT Imaging
Drug · Diagnostic Test
Lead sponsor
NexEos Diagnostics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 17, 2026, 4:31 AM EDT
Recruiting Phase 2 Interventional

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07298395
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
ENV-294, Placebo
Drug
Lead sponsor
Enveda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
32
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

NCT00833495
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 17, 2026, 4:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sensitization Study of ATx201 in Healthy Volunteers

NCT03375957
View directory record Official record
Conditions
Sensitivity, Contact
Interventions
ATx201, ATx201 Placebo Gel
Drug
Lead sponsor
UNION therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 17, 2026, 4:31 AM EDT
Completed Not applicable Interventional Results available

Cooling Pillow for Atopic Dermatitis

NCT01132651
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Current standard eczema treatment and standard pillow at night, Chillow cooling pillow
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 17, 2026, 4:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Exercise Training Intensity on Fitness and Insulin Sensitivity in African Americans

NCT02892331
View directory record Official record
Conditions
Obesity, Insulin Resistance, Sedentary Lifestyle
Interventions
Moderate intensity exercise training (MOD-INT), High Intensity exercise training (HI-INT)
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
35 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 17, 2026, 4:31 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

NCT05579730
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035%, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Andover, Massachusetts • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 17, 2026, 4:31 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Polarization Sensitive Optical Coherence Tomography (PS-OCT) for Retinal Imaging

NCT02441777
View directory record Official record
Conditions
Healthy
Interventions
Polarization-Sensitive OFDI
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 17, 2026, 4:31 AM EDT
Not yet recruiting Not applicable Interventional

Use of Silk Fibroin Dressings in Primary Total Hip Arthroplasty

NCT07868900
View directory record Official record
Conditions
Allergic Contact Dermatitis (ACD)
Interventions
Dermabond PRINEO, Silk fibroin
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 4:31 AM EDT
Completed No phase listed Observational

Registry of Asthma Patients Initiating DUPIXENT®

NCT04287621
View directory record Official record
Conditions
Asthma
Interventions
DUPIXENT®
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
73
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 17, 2026, 4:31 AM EDT
Completed Phase 3 Interventional Results available

Phase III Cat-PAD Study

NCT01620762
View directory record Official record
Conditions
Rhinoconjunctivitis
Interventions
Cat-PAD, Placebo
Drug
Lead sponsor
Circassia Limited
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
52
States / cities
Rolling Hills Estates, California • Colorado Springs, Colorado • Denver, Colorado + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 17, 2026, 4:31 AM EDT
Withdrawn Phase 3 Interventional

Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation

NCT05292976
View directory record Official record
Conditions
Bronchial Asthma
Interventions
Methacholine Chloride, Albuterol Sulfate HFA 0.09 mg (Reference), Albuterol Sulfate HFA 0.18 mg (Reference), Albuterol Sulfate HFA 0.09 mg (Test), Albuterol Sulfate HFA 0.18 mg (Test), Placebo
Other · Drug
Lead sponsor
Aurobindo Pharma Ltd
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 17, 2026, 4:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sickle Cell Pro-Inflammatory Response to Interval Training Study

NCT03653676
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Exercise Test (CIIT)
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
10 Years to 21 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 17, 2026, 4:31 AM EDT
Completed Phase 3 Interventional

Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma

NCT00064389
View directory record Official record
Conditions
Asthma
Interventions
levalbuterol tartrate HFA MDI, racemic albuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
91
States / cities
Birmington, Alabama • Mobile, Alabama • Montgomery, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 17, 2026, 4:31 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

NCT01881113
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 17, 2026, 4:31 AM EDT